Immune checkpoint inhibitor combination efficacious for patients with high-grade neuroendocrine ...

Prof Sandip Patel gives a press conference at AACR 2019 on results from the DART phase II trial which showed the combination of ipilimumab and nivolumab to have clinical benefit when treating high-grade neuroendocrine carcinoma.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php